IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference

Rhea-AI Summary

IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will present at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 12:00pm ET. The conference will showcase IN8bio’s innovative gamma-delta T cell therapies for solid and liquid tumors, emphasizing their unique ability to differentiate healthy from diseased tissues. Currently, IN8bio is conducting two Phase 1 clinical trials for its leading candidates: INB-200 targeting glioblastoma and INB-100 for leukemia patients. A Phase 2 trial, INB-400, is also set to begin post-IND clearance. For further details, visit IN8bio.com.

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley Securities’ 3^rd Annual Oncology Conference on Wednesday, January 18, 2023 at 12:00pm ET.

Interested parties can register for the webcast using the B. Riley Securities conference website:

https://brileyoncology22.sequireevents.com/

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com

Investors & Media Contact:
Argot Partners
IN8bio@argotpartners.com

FAQ

When is IN8bio's presentation at the B. Riley Securities’ Oncology Conference?

IN8bio's presentation is scheduled for January 18, 2023, at 12:00pm ET.

What is the focus of IN8bio's gamma-delta T cell therapies?

IN8bio focuses on developing therapies for solid and liquid tumors, utilizing gamma-delta T cells.

What clinical trials is IN8bio currently conducting?

IN8bio is conducting Phase 1 trials for INB-200 targeting glioblastoma and INB-100 for leukemia patients.

What is the purpose of the INB-400 trial initiated by IN8bio?

The INB-400 trial aims to treat newly diagnosed glioblastoma and follows IND clearance in late 2022.

Where can I find more information about IN8bio?

More information about IN8bio can be found on their official website at www.IN8bio.com.